• Roche Diagnostics shipped two molecular testing instruments to Congo’s INSP to expand Ebola testing capacity in the DRC.
• Equipment targets Bundibugyo virus detection; Roche developed a research-use-only PCR test in June.
• INSP will validate locally in Bunia; additional test shipments and instrument deployments expected once validation is complete.
• UN data as of Sept. 28, 2026 showed 8,067 confirmed cases, 3,901 deaths; case fatality rate 48.4%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610070100PR_NEWS_USPR_____SF65380) on October 07, 2026, and is solely responsible for the information contained therein.